Mar 15, 2019 - CTLT vs. NBIX: Which Stock Is the Better Value Option?
Mar 12, 2019 - Orbimed Advisors Llc Buys Guardant Health Inc, CVS Health Corp, Celgene Corp, Sells Jazz Pharmaceuticals PLC, Alexion Pharmaceuticals Inc, Bristol-Myers Squibb Company, Stocks: CELG,ISRG,BHC,CNC,NBIX,DCPH,GH,CVS,DXCM,MYOK,THC,I, release date:Mar 11, 2019
Feb 27, 2019 - Neurocrine recently nabbed a deal with Voyager Therapeutics for a gene therapy program. The program is well within Neurocrine's scope of movement disorders, as it targets Parkinson's disease. The deal
Feb 12, 2019 - CTLT vs. NBIX: Which Stock Is the Better Value Option?
Feb 11, 2019 - AXON has confirmed initial data are coming from two trials in March.I take a look at AXO-Lenti-PD and previous data with ProSavin.I take a look at other data with Parkinson's disease gene therapies.I
Feb 08, 2019 - Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018, Stocks: NBIX, release date:Feb 08, 2019
Feb 06, 2019 - The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2018 Q4 earnings call.
Feb 05, 2019 - NBIX earnings call for the period ending December 31, 2018.
Feb 05, 2019 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2018 Earnings Conference Call February 5, 2019 4:30 PM ET Company Participants Kevin Gorman – Chief Executive Officer Jane Sorensen – Head-Investor Relati
Jan 30, 2019 - Neurocrine has chosen to in-license some early-stage CNS gene therapy assets that could significantly build its movement disorder franchise down the line. Voyager's lead candidate targets restoring AA